September 8, 2021 at 7:01 AM EDT
DUBLIN, Ireland and FORT WASHINGTON, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) — Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced today that its partner, Sumitomo Pharmaceuticals (Suzhou) Co., Ltd. has received approval to market oral and intravenous (IV) formulations of XENLETA® (lefamulin) for the treatment of community-acquired pneumonia (CAP) in adults in Taiwan.
In May 2021, Nabriva entered into an agreement for the development and commercialization rights for lefamulin in the greater China Region to Sumitomo Pharmaceuticals (Suzhou), the Chinese affiliate of Sumitomo Dainippon Pharma. The anticipated launch timing of XENLETA® in Taiwan is undecided.
Full PR available here